[go: up one dir, main page]

MX2009011865A - Tratamiento de lesiones viralmente inducidas. - Google Patents

Tratamiento de lesiones viralmente inducidas.

Info

Publication number
MX2009011865A
MX2009011865A MX2009011865A MX2009011865A MX2009011865A MX 2009011865 A MX2009011865 A MX 2009011865A MX 2009011865 A MX2009011865 A MX 2009011865A MX 2009011865 A MX2009011865 A MX 2009011865A MX 2009011865 A MX2009011865 A MX 2009011865A
Authority
MX
Mexico
Prior art keywords
treatment
lesions
papilloma virus
virally induced
induced lesions
Prior art date
Application number
MX2009011865A
Other languages
English (en)
Inventor
Steven Martin Ogbourne
Andreas Suhrbier
James Harrison Aylward
Original Assignee
Peplin Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39925109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011865(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2007902266A external-priority patent/AU2007902266A0/en
Application filed by Peplin Research Pty Ltd filed Critical Peplin Research Pty Ltd
Publication of MX2009011865A publication Critical patent/MX2009011865A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere en general al tratamiento de lesiones cutáneas que contienen células infectadas a través de un virus, así como a composiciones para el tratamiento de tales lesiones. Más específicamente, la invención se refiere al uso de compuestos de ingenol, particularmente angelatos de ingenol, para tratar lesiones causadas por infección con un virus de papiloma, tal como un virus de papiloma de mamífero, en particular un virus de Papiloma Humano.
MX2009011865A 2007-04-30 2008-04-30 Tratamiento de lesiones viralmente inducidas. MX2009011865A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007902266A AU2007902266A0 (en) 2007-04-30 Treatment of virally induced lesions
PCT/AU2008/000596 WO2008131491A1 (en) 2007-04-30 2008-04-30 Treatment of virally induced lesions

Publications (1)

Publication Number Publication Date
MX2009011865A true MX2009011865A (es) 2009-12-04

Family

ID=39925109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011865A MX2009011865A (es) 2007-04-30 2008-04-30 Tratamiento de lesiones viralmente inducidas.

Country Status (22)

Country Link
US (1) US9895334B2 (es)
EP (1) EP2152261B1 (es)
JP (1) JP5497629B2 (es)
KR (1) KR101485883B1 (es)
CN (1) CN101742996B (es)
AU (1) AU2008243705B2 (es)
BR (1) BRPI0810806A2 (es)
CA (1) CA2685473C (es)
CY (1) CY1119269T1 (es)
DK (1) DK2152261T3 (es)
ES (1) ES2564173T3 (es)
HR (1) HRP20160181T1 (es)
HU (1) HUE028713T2 (es)
IL (1) IL201796A (es)
MX (1) MX2009011865A (es)
MY (1) MY154484A (es)
NZ (1) NZ580702A (es)
PL (1) PL2152261T3 (es)
RU (1) RU2506951C2 (es)
SI (1) SI2152261T1 (es)
UA (1) UA98328C2 (es)
WO (1) WO2008131491A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
CA2589992C (en) 2004-12-13 2014-04-22 Peplin Research Pty Ltd Treatment of solid cancers
US9895334B2 (en) 2007-04-30 2018-02-20 Leo Laboratories Limited Treatment of virally induced lesions
ES2633755T3 (es) 2009-02-13 2017-09-25 Leo Laboratories Limited Tratamiento de la piel
WO2011128780A1 (en) 2010-04-16 2011-10-20 Leo Pharma A/S Crystalline ingenol mebutate
US9402823B2 (en) 2010-12-17 2016-08-02 Leo Laboratories Limited Ingenols for treating seborrheic keratosis
TWI548616B (zh) * 2010-12-22 2016-09-11 理奧實驗有限公司 巨大戟萜醇－３－醯化物iii及巨大戟萜醇－３－胺基甲酸酯化物
US9388124B2 (en) 2010-12-22 2016-07-12 Leo Laboratories Limited Ingenol-3-acylates I
US9656945B2 (en) 2010-12-22 2017-05-23 Leo Laboratories Limited 3-acyl-ingenols II
WO2012176015A1 (en) 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
KR101406201B1 (ko) * 2011-10-19 2014-06-12 한국생명공학연구원 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
CN104136081B (zh) * 2012-03-02 2018-05-15 阿马佐尼亚菲托药品有限公司 再活化潜伏hiv病毒的巨大戟二萜醇衍生物
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
IN2014DN11023A (es) * 2012-06-26 2015-09-25 Leo Lab Ltd
GB201222406D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
US20150320679A1 (en) * 2012-12-12 2015-11-12 Leo Laboratories Limited Gel compositions
GB201222403D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
EP3007676A1 (en) * 2013-06-12 2016-04-20 Leo Laboratories Limited A topical composition
KR101520428B1 (ko) * 2013-11-22 2015-05-14 충남대학교산학협력단 대극 추출물을 유효성분으로 포함하는 항인플루엔자용 조성물
CN104188979B (zh) * 2014-08-11 2017-01-11 泰州祥泰康华医药科技有限公司 闭花木酮Cleistanone的O-(吗啉基)乙基衍生物在制备治疗缺血性脑损伤药物中的应用
CN104523705A (zh) * 2014-12-10 2015-04-22 南京大学 闭花木酮的o-(咪唑基)乙基衍生物在制备抗病毒药物中的应用
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
JP7495679B2 (ja) * 2019-10-03 2024-06-05 国立大学法人京都大学 ヒトパピローマウイルス性疣贅に対する貼付剤
EP3915549A1 (en) * 2020-05-26 2021-12-01 Merck Patent GmbH Senescence inducers for use in the treatment and/or prevention of virus induced diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804203A (en) * 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
RU2174396C2 (ru) * 1997-03-20 2001-10-10 Панацея Биотек Лтд. Фармацевтическая композиция для подавления и лечения аноректальных и ободочно-кишечных болезней
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
CA2589992C (en) 2004-12-13 2014-04-22 Peplin Research Pty Ltd Treatment of solid cancers
EP1951221A1 (en) * 2005-11-14 2008-08-06 Peplin Research Pty Ltd. Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer
GB0525680D0 (en) * 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
US9895334B2 (en) 2007-04-30 2018-02-20 Leo Laboratories Limited Treatment of virally induced lesions

Also Published As

Publication number Publication date
PL2152261T3 (pl) 2016-06-30
HUE028713T2 (en) 2016-12-28
BRPI0810806A2 (pt) 2014-10-29
EP2152261B1 (en) 2015-12-09
KR20100017464A (ko) 2010-02-16
US9895334B2 (en) 2018-02-20
DK2152261T3 (en) 2016-03-07
IL201796A (en) 2016-11-30
EP2152261A1 (en) 2010-02-17
HRP20160181T1 (hr) 2016-05-06
WO2008131491A1 (en) 2008-11-06
UA98328C2 (uk) 2012-05-10
RU2506951C2 (ru) 2014-02-20
NZ580702A (en) 2012-03-30
SI2152261T1 (sl) 2016-05-31
IL201796A0 (en) 2010-06-16
EP2152261A4 (en) 2013-01-02
AU2008243705A1 (en) 2008-11-06
CA2685473C (en) 2015-09-01
CA2685473A1 (en) 2008-11-06
JP5497629B2 (ja) 2014-05-21
CY1119269T1 (el) 2018-02-14
JP2010524978A (ja) 2010-07-22
KR101485883B1 (ko) 2015-01-27
AU2008243705B2 (en) 2013-10-10
HK1134450A1 (zh) 2010-04-30
CN101742996A (zh) 2010-06-16
ES2564173T3 (es) 2016-03-18
CN101742996B (zh) 2013-08-21
MY154484A (en) 2015-06-30
RU2009144100A (ru) 2011-06-10
US20100204318A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
MX2009011865A (es) Tratamiento de lesiones viralmente inducidas.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MA33939B1 (fr) 5-alcynyl-pyrimidines
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
BR112012009214A2 (pt) compostos
EA201100390A1 (ru) Соединения для лечения гепатита с
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
TN2012000416A1 (en) Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
JO3204B1 (ar) 4- أريل-n- فنيل-5،3،1- ترايازين-2- أمينات محتوية على مجموعة سلفوكسيمين
EA201100794A1 (ru) Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
EA201100255A1 (ru) 5-алкинилпиримидины
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
EA201001427A1 (ru) Тиазолилдигидроиндазолы
EA201001748A1 (ru) Соединения, используемые для лечения гепатита с
EA201270798A1 (ru) Соединения для лечения гепатита с
TN2011000531A1 (en) 5- alkynyl - pyridines
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.
NZ596158A (en) Thioxanthene derivatives for the treatment of infectious diseases

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: LEO LABORATORIES LIMITED.*

FG Grant or registration